ANNX combines a confirmed bullish technical breakout with notable insider buying and a solid earnings track record, but quality sitting well below the required floor and elevated short and put positioning keep this a speculative, binary biotech bet.
Thesis pillars
- Notable Insider Buying→Stable
- Quality Below Required Floor→Stable
- Confirmed Breakout Momentum→Stable
- +2 more pillars — see the Why tab for full reasoning
Annexon, Inc. (ANNX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.06: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality.
Annexon is a clinical-stage biopharmaceutical company developing targeted immunotherapies that block the classical complement pathway at C1q for neuroinflammatory diseases affecting nearly 10 million people worldwide. Its two lead registrational programs are tanruprubart, aiming... Read more
Sell if holding. Engine safety override at $6.06: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.9/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Annexon, Inc.
About Annexon, Inc.
Annexon's two lead registrational programs, tanruprubart for Guillain-Barre Syndrome (GBS) and vonaprument for geographic atrophy (GA), anchor a pipeline built on inhibiting C1q, the initiating molecule of the classical complement cascade. GBS affects approximately 150,000 people annually worldwide, including 22,000 in the U.S. and EU, and Annexon filed a Marketing Authorization Application with the European Medicines Agency for tanruprubart in January 2026. The clinical-stage company reported a $206.7 million net loss in 2025 and held $238.3 million in cash and short-term investments as of December 31, 2025.
As a pre-revenue biopharmaceutical company, Annexon funds research and development primarily through equity issuance rather than product sales; in March 2026 the company entered an at-the-market sales agreement with TD Cowen for up to $150 million of common stock. Its pipeline centers on full inhibition of the classical complement cascade upstream at C1q, a target for which the company holds worldwide development and commercialization rights across all product candidates. Tanruprubart completed a placebo-controlled Phase 3 trial in GBS, in which roughly 90% of treated patients improved by week 1, and has received FDA Fast Track and orphan drug designation plus EMA orphan designation; an ongoing open-label FORWARD study in the U.S. and Europe is meant to broaden the data package ahead of a planned 2026 BLA submission. Vonaprument completed enrollment of 659 patients in the Phase 3 ARCHER II trial for GA in July 2025, with topline data expected in the fourth quarter of 2026, and the company relies on third-party contract manufacturers and contract research organizations to run trials and produce clinical supply.
Show full overview
Annexon's near-term value is concentrated in two clinical readouts rather than a diversified portfolio: the company states its resources are primarily focused on advancing tanruprubart in GBS and vonaprument in GA, with no other program past Phase 2. Vonaprument's ARCHER II topline data, due in the fourth quarter of 2026, will determine whether the drug becomes the first therapy approved in the U.S. and Europe to protect vision in geographic atrophy, after previously showing a more than 70% reduction in risk of 15-letter vision loss in the Phase 2 ARCHER trial; a negative or ambiguous readout would leave GBS as Annexon's sole near-term registrational path.
See also: Healthcare · Biotechnology
From Annexon, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelinetanruprubart and vonaprument lead programs10-K Item 1A: 'Our resources are primarily focused on advancing tanruprubart in GBS, and vonaprument in GA.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.06: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $5.54. Score 5.9/10, moderate confidence.
Take-profit target: $11.42 (+91.6% upside). Prior stop was $5.54. Stop-loss: $5.54.
Quality below floor (1.8 < 4.0).
Annexon, Inc. trades at a P/E of N/A (forward -6.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover ANNX with a consensus score of 4.1/5. Average price target: $13.
What does Annexon, Inc. do?Annexon is a clinical-stage biopharmaceutical company developing targeted immunotherapies that block the classical...
Annexon is a clinical-stage biopharmaceutical company developing targeted immunotherapies that block the classical complement pathway at C1q for neuroinflammatory diseases affecting nearly 10 million people worldwide. Its two lead registrational programs are tanruprubart, aiming for approval in Guillain-Barre Syndrome (GBS), and vonaprument, in Phase 3 for geographic atrophy (GA); the company has no products approved for sale and reported a $206.7 million net loss in 2025 against $238.3 million in cash and short-term investments. Annexon holds worldwide development and commercialization rights